Healthcare Industry News: metabolic disease
News Release - May 13, 2011
Teijin Pharma to Launch Feburic(r) (febuxostat) in JapanFirst Drug for Chronic Management of Hyperuricemia in 40 Years
Tokyo, Japan, May 13, 2011 --(Healthcare Sales & Marketing Network)-- Teijin Pharma Limited (www.teijin-pharma.co.jp/english/index.html), the core company of the Teijin Group's (www.teijin.co.jp/english) medical and pharmaceutical business, announced today that it will launch Feburic(r) (febuxostat, TMX-67), Teijin Pharma's novel drug for treating hyperuricemia, in Japan on May 17.
Feburic(r), a highly potent oral drug taken once daily, is the first drug indicated for treatment of hyperuricemia with or without symptoms (e.g. gout, hypertension, etc.) in Japan. It effectively lowers the level of uric acid in the blood of hyperuricemic patients to the recommended level of less than 6.0mg/dL, and is well tolerated by patients suffering from mild to moderate renal impairment without any dose adjustment. In Japan, the number of patients with hyperuricemia is estimated to be around 16 million.
Discovered by Teijin Pharma in 1991, febuxostat is the world's first non-purine selective inhibitor of xanthine oxidase. It has a novel chemical structure completely different from that of allopurinol, which has been used for over 40 years as the standard treatment for hyperuricemia.
Febuxostat already is marketed by licensees under the brand name Uloric(r) in the U.S. and Canada, and under the brand name Adenuric(r) in Europe including France, the U.K., Germany, Ireland, Italy, Greece and Austria as treatment of hyperuricemia in patients with gout. Collaborative efforts with licensees in other markets such as China, Korea, Hong Kong, Taiwan, Mexico, the Caribbean and Middle East and North African (MENA) regions are aimed at launching the drug in these markets as well. In Japan, Teijin Pharma obtained approval to market the drug from the Ministry of Health, Labor and Welfare this past January.
Teijin Pharma has positioned febuxostat as a global strategic product and expects to achieve global annual sales of over 100 billion yen for the drug in the foreseeable future.
About Teijin Pharma Limited
Teijin Pharma Limited, the core company of Teijin Group's medical and pharmaceuticals business, focuses on three key therapeutic areas: respiratory, bone/joint, and cardiovascular/metabolic diseases. Teijin Pharma has strong marketing positions, particularly in the respiratory and bone/joint areas, with pharmaceutical products as well as a home healthcare business, including home oxygen therapy. Teijin Pharma continues to enhance its presence worldwide through in-house R&D as well as in-licensing and out-licensing activities. Please visit www.teijin-pharma.co.jp/english/index.html
About the Teijin Group
Based in Tokyo and Osaka, Japan, Teijin is a global technology-driven group operating in eight main fields: aramid fibers, carbon fibers & composites, polyester fibers, plastics, films, medical & pharmaceuticals, fiber products marketing and IT businesses. Teijin Limited, the holding company for the Teijin Group, is listed on the Tokyo and Osaka stock exchanges. The group, comprising 150 companies and 17,542 employees worldwide, had consolidated sales of JPY 815.7 billion (USD 9.8 billion) and total assets of JPY 761.5 billion (USD 9.2 billion) in the fiscal year ending March 31, 2011. Please visit www.teijin.co.jp/english Press Contact Rie Mashiba Public Relations & Investor Relations Office Teijin Limited +81 3 3506 4055
Source: Teijin Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.